Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Immatics reports Q3 EPS (EUR 0.32) vs (EUR 0.43) last year » 07:08
11/17/22
11/17
07:08
11/17/22
07:08
IMTX

Immatics

$10.31 /

-0.3 (-2.83%)

Reports Q3 revenue EUR…

Reports Q3 revenue EUR 15.060M vs EUR 6.443M last year. "The initial results from our Phase 1a and Phase 1b cohort A showed a highly encouraging confirmed objective response rate of 50% for patients treated at or above target dose. Early data from cohort A alone have shown a confirmed objective response rate of 80%. With these encouraging results, we have built momentum for our multi-cohort strategy designed to leverage the full clinical potential of targeting PRAME," commented Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics. "We look forward to sharing the next data readouts from all three Phase 1b expansion cohorts in 2023, as well as initiating the Phase 1/2 clinical trial of our TCR Bispecific candidate, TCER IMA402, targeting PRAME. With the recent addition of new capital, we have the resources to deliver on our corporate objectives for 2023 and to fund operations into 2025."

ShowHide Related Items >><<
IMTX Immatics
$10.31 /

-0.3 (-2.83%)

IMTX Immatics
$10.31 /

-0.3 (-2.83%)

10/10/22 Chardan
Immatics' TCR-T data validate potential best-in-class profile, says Chardan
08/09/22 Chardan
Immatics price target lowered to $28 from $30 at Chardan
12/14/21 SVB Securities
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
12/14/21 SVB Securities
Immatics price target raised to $32 from $28 at SVB Leerink
IMTX Immatics
$10.31 /

-0.3 (-2.83%)

  • 13
    Oct
Over a month ago
Recommendations
Immatics' TCR-T data validate potential best-in-class profile, says Chardan » 19:50
10/10/22
10/10
19:50
10/10/22
19:50
IMTX

Immatics

$11.21 /

+1.11 (+10.99%)

Chardan analyst Geulah…

Chardan analyst Geulah Livshits keeps her Buy rating and $28 price target on Immatics after the company's data on PRAME-targeting TCR T cell therapy IMA203. The results help validate PRAME as a clinical target with what is a potentially best-in-class profile, and she increases her launch probability for IMA203 from 35% to 40%, Livshits tells investors in a research note.

ShowHide Related Items >><<
IMTX Immatics
$11.21 /

+1.11 (+10.99%)

IMTX Immatics
$11.21 /

+1.11 (+10.99%)

08/09/22 Chardan
Immatics price target lowered to $28 from $30 at Chardan
12/14/21 SVB Securities
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
12/14/21 SVB Securities
Immatics price target raised to $32 from $28 at SVB Leerink
IMTX Immatics
$11.21 /

+1.11 (+10.99%)

  • 13
    Oct
Hot Stocks
Immatics reports interim clinical data update on ACTengine IMA203 » 07:47
10/10/22
10/10
07:47
10/10/22
07:47
IMTX

Immatics

$10.11 /

-0.33 (-3.16%)

Immatics announced a…

Immatics announced a clinical data update for the IMA203 monotherapy covering the completed Phase 1a dose escalation part of the trial and initial data from the first 5 patients in the ongoing Phase 1b dose expansion cohort A. In the Phase 1 trial with ACTengine IMA203, Immatics is treating recurrent and/or refractory solid cancer patients utilizing TCR-T cells directed against an HLA-A*02-presented peptide derived from PRAME, which is frequently expressed across several solid cancer indications. Overall, IMA203 continues to be well tolerated and achieved confirmed objective responses across multiple solid cancers such as cutaneous melanoma, ovarian cancer, head and neck cancer, uveal melanoma, and synovial sarcoma. Encouraging early signs of improved durability were seen with a 50% confirmed objective response rate, when patients were infused at the target dose or above with more than 1 billion TCR-T cells. The data obtained during the Phase 1a and Phase 1b cohort A trial provide clinical validation of PRAME as a highly promising T cell target for solid cancers. Confirmed clinical responses were observed at high and low PRAME-expression levels above threshold, indicating IMA203's potential to provide clinical benefit for all PRAME biomarker-positive cancer patients. The predicted high PRAME prevalence across key indications has so far been supported by prevalence rates obtained during the clinical screening of patients. Moving from Phase 1a to Phase 1b, Immatics has continued to introduce planned improvements that may influence clinical outcomes including applying higher cell doses, optimizing the cell product through manufacturing enhancements and working with disease area experts to gradually reduce the fraction of very heavily pre-treated patients with extreme tumor burden who have exhausted standard of care and have undergone multiple clinical trials. In addition, the focus in Phase 1b is also shifting from initial objective response rate determined at the ~6-week scan to confirmed ORR determined at the ~12-week scan. Positively evolving durability profile for IMA203 was observed at higher doses: 6 of 12 patients treated with more than 1 billion infused TCR-T cells in the Phase 1a and Phase 1b cohort A part of the trial experienced a confirmed objective response. In the Phase 1b part of the trial alone, 4 of 5 patients had a confirmed objective response which were all ongoing at the timepoint of data cut-off. Safety data for IMA203 monotherapy across Phase 1a and Phase 1b: Treatment with IMA203 continues to show manageable tolerability profile. At data cut-off on September 6, 2022, 32 patients were infused with IMA203 TCR-T cells. Most frequent treatment-emergent adverse events were as expected for cell therapies. All patients experienced expected cytopenia associated with lymphodepletion. 31 patients experienced cytokine release syndrome of any grade: 29 patients had low to moderate, and 2 patients had Grade 3 CRS that occurred in Phase 1a; both recovered to Grade less than or equal to2 after 3 and 4 days. 5 patients experienced a low to moderate immune effector cell associated neurotoxicity syndrome. No dose-dependent increase of CRS and ICANS was observed. No additional dose limiting toxicities were observed since the initial data release in March 2021. Phase 1a - Clinical activity: IMA203 demonstrated a high initial objective response rate in several solid tumor types. At data cut-off on September 6, 2022, a total of 27 patients received IMA203 monotherapy in the Phase 1a dose escalation trial: High initial objective response rate of 48% was observed at the first CT scan post infusion at ~week 6, and a confirmed ORR of 19% the second CT scan at ~week 12. 7 out of 27 patients received doses above 1 billion TCR-T cells; initial ORR was 57% and confirmed ORR was 29% in these patients. Patients were heavily pre-treated with a mean of 4.2 lines of prior systemic treatment and a particularly high baseline tumor burden. The provisional recommended Phase 2 dose for Phase 1b dose expansion was determined to be DL4. Phase 1b Cohort A - Clinical activity: IMA203 monotherapy demonstrates high confirmed objective response rate of 80% with early signs of prolonged durability. At data cut-off on September 6, 2022, 5 patients received IMA203 monotherapy at DL4 and DL5 in the Phase 1b cohort A dose expansion trial: 4 out of 5 patients experienced an initial objective response at ~week 6. In all 4 patients, objective responses were confirmed at ~week 12 and were ongoing at data cut-off: confirmed ORR was 80%. All 4 responses were observed in different solid tumor types: cutaneous melanoma, ovarian cancer, uveal melanoma and head and neck cancer. Patients were heavily pre-treated with a mean of 4.0 lines of prior systemic treatment and high to moderate baseline tumor burden.

ShowHide Related Items >><<
IMTX Immatics
$10.11 /

-0.33 (-3.16%)

IMTX Immatics
$10.11 /

-0.33 (-3.16%)

08/09/22 Chardan
Immatics price target lowered to $28 from $30 at Chardan
12/14/21 SVB Securities
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
12/14/21 SVB Securities
Immatics price target raised to $32 from $28 at SVB Leerink
IMTX Immatics
$10.11 /

-0.33 (-3.16%)

  • 13
    Oct
Syndicate
Immatics 10.905M share Secondary priced at $10.09 » 07:41
10/10/22
10/10
07:41
10/10/22
07:41
IMTX

Immatics

$10.11 /

-0.33 (-3.16%)

Jefferies and SVB…

Jefferies and SVB Securities acted as joint book running managers for the offering.

ShowHide Related Items >><<
IMTX Immatics
$10.11 /

-0.33 (-3.16%)

IMTX Immatics
$10.11 /

-0.33 (-3.16%)

08/09/22 Chardan
Immatics price target lowered to $28 from $30 at Chardan
12/14/21 SVB Securities
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
12/14/21 SVB Securities
Immatics price target raised to $32 from $28 at SVB Leerink
IMTX Immatics
$10.11 /

-0.33 (-3.16%)

Syndicate
Immatics announces $110M underwritten offering of common stock » 07:40
10/10/22
10/10
07:40
10/10/22
07:40
IMTX

Immatics

$10.11 /

-0.33 (-3.16%)

Immatics N.V.…

Immatics N.V. "announced that it has agreed to sell, by way of an underwritten public offering, 10,905,000 of its ordinary shares at a price of $10.09 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $110 million. The offering is expected to close on October 12, 2022, subject to customary closing conditions. Jefferies and SVB Securities are acting as joint book-running managers for the offering."

ShowHide Related Items >><<
IMTX Immatics
$10.11 /

-0.33 (-3.16%)

IMTX Immatics
$10.11 /

-0.33 (-3.16%)

08/09/22 Chardan
Immatics price target lowered to $28 from $30 at Chardan
12/14/21 SVB Securities
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
12/14/21 SVB Securities
Immatics price target raised to $32 from $28 at SVB Leerink
IMTX Immatics
$10.11 /

-0.33 (-3.16%)

Conference/Events
Immatics management to meet with Jefferies » 17:25
09/29/22
09/29
17:25
09/29/22
17:25
IMTX

Immatics

$9.75 /

+0.27 (+2.85%)

Biotech Analyst Shi to…

Biotech Analyst Shi to hold a group dinner meeting with CEO Singh in New York on September 29 at 6 pm hosted by Jefferies.

ShowHide Related Items >><<
IMTX Immatics
$9.75 /

+0.27 (+2.85%)

IMTX Immatics
$9.75 /

+0.27 (+2.85%)

08/09/22 Chardan
Immatics price target lowered to $28 from $30 at Chardan
12/14/21 SVB Securities
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
12/14/21 SVB Securities
Immatics price target raised to $32 from $28 at SVB Leerink
IMTX Immatics
$9.75 /

+0.27 (+2.85%)

Conference/Events
Immatics management to meet with Jefferies » 12:00
09/29/22
09/29
12:00
09/29/22
12:00
IMTX

Immatics

$9.43 /

-0.05 (-0.53%)

Biotech Analyst Shi to…

Biotech Analyst Shi to hold a group dinner meeting with CEO Singh in New York on September 29 at 6 pm hosted by Jefferies.

ShowHide Related Items >><<
IMTX Immatics
$9.43 /

-0.05 (-0.53%)

IMTX Immatics
$9.43 /

-0.05 (-0.53%)

08/09/22 Chardan
Immatics price target lowered to $28 from $30 at Chardan
12/14/21 SVB Securities
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
12/14/21 SVB Securities
Immatics price target raised to $32 from $28 at SVB Leerink
IMTX Immatics
$9.43 /

-0.05 (-0.53%)

Hot Stocks
Immatics presents comprehensive preclinical data set for IMA402 targeting PRAME » 11:03
09/10/22
09/10
11:03
09/10/22
11:03
IMTX

Immatics

$12.84 /

-0.215 (-1.65%)

Immatics announced a…

Immatics announced a comprehensive preclinical data set for its T cell engaging receptor product candidate IMA402 at the European Society for Medical Oncology Congress 2022 held in Paris, France, from September 9 to 13, 2022. IMA402 is the company's second program in its TCR Bispecifics pipeline and is directed against an HLA-A*02:01-presented peptide derived from PRAME, a cancer target broadly expressed in many solid tumors. The IMA402 TCER utilizes a high-affinity TCR designed to specifically bind to an HLA-A*02:01-presented peptide derived from PRAME on tumor cells. The T cell recruiter domain is a proprietary low-affinity T cell recruiter against the TCR/CD3 complex that demonstrates superior in vivo tumor control compared to analogous TCER molecules designed with higher-affinity variants of a widely used antibody recruiter. The IMA402 TCER is optimized to reduce T cell engager-associated toxicities in patients, which is demonstrated by reduced recruiter-mediated cytokine release in vitro. IMA402 showed potent and selective activity against PRAME-positive tumor cell lines in vitro. In vivo studies in mice demonstrated dose-dependent anti-tumor activity of IMA402. Sufficiently high drug doses were key to achieving the desired anti-tumor effects over a prolonged period. In vitro safety assessment including toxicity screening against 20 normal tissue types, whole blood cytokine release assessment and alloreactivity evaluation confirmed favorable safety profile for IMA402. The half-life extended format of IMA402 confers a serum half-life of greater than1 week in mice suggesting a favorable dosing regimen and prolonged drug exposure at therapeutic levels when compared to TCR Bispecifics lacking half-life extension strategies. To enable the start of the Phase 1/2 trial in 2023, Immatics has completed the manufacturing process development for IMA402 and manufacturing of the clinical batch is on track for the second half of 2022. The Phase 1 part of the trial will start with a minimal anticipated biological effect level dose of IMA402 and will have an adaptive design aimed at accelerating dose escalation to determine the recommended Phase 2 dose. HLA-A*02:01-positive patients with different solid tumors expressing PRAME will initially receive weekly infusions of IMA402. Pharmacokinetics data will be assessed throughout the trial and might provide an opportunity to adapt the treatment interval. The Phase 2a dose expansion part of the trial will be designed to comprise several cohorts to further evaluate IMA402 in specific indications and combination therapies. Submission of the IND1 application is planned for Q2 2023.

ShowHide Related Items >><<
IMTX Immatics
$12.84 /

-0.215 (-1.65%)

IMTX Immatics
$12.84 /

-0.215 (-1.65%)

08/09/22 Chardan
Immatics price target lowered to $28 from $30 at Chardan
12/14/21 SVB Securities
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
12/14/21 SVB Securities
Immatics price target raised to $32 from $28 at SVB Leerink
IMTX Immatics
$12.84 /

-0.215 (-1.65%)

Over a quarter ago
Hot Stocks
Immatics announces first cancer patient treated with IMA203CD8 » 07:10
08/23/22
08/23
07:10
08/23/22
07:10
IMTX

Immatics

$11.40 /

+0.17 (+1.51%)

Immatics announced the…

Immatics announced the treatment of the first patient in its Phase 1b expansion cohort C evaluating IMA203CD8, the company's 2nd generation TCR-T monotherapy approach where a proprietary CD8alphabeta co-receptor is added to PRAME-specific IMA203 T cells. The CD8 co-receptor plays an important role during T cell antigen recognition and T cell activation, enabling the effective engagement of CD8 and CD4 T cells in the anti-tumor response. "IMA203CD8's unique mode of action has been validated by preclinical data presented at SITC last year, which demonstrated sustained suppression of tumor growth in serial killing experiments. With the initiation of the IMA203CD8 cohort, we can now test to what extent the interplay of engineered CD8 and CD4 T cells enhances anti-tumor activity in the clinical setting," said Dr. Cedrik Britten, M.D., Chief Medical Officer at Immatics. "Today's milestone brings us closer to our goal of achieving long-lasting responses for a broad range of cancer patients having solid tumors that express PRAME." The importance of CD4 T cells for the duration of responses has been demonstrated by Immatics in preclinical assays where IMA203CD8 showed enhanced potency and prolonged anti-tumor activity compared to IMA203 alone. The IMA203CD8 Phase 1b dose expansion cohort is expected to enroll up to 24 patients with different types of solid tumors across several clinical trial sites in the U.S. and in Germany. Following personalized manufacturing and lymphodepletion, patients will receive a single dose of IMA203CD8. The primary objective of this Phase 1b cohort is to evaluate the safety profile of IMA203CD8. Secondary objectives include evaluating initial anti-tumor and biological activity. The 2nd generation TCR-T IMA203CD8 is part of Immatics' strategy to realize the full clinical potential of IMA203 TCR-T targeting PRAME. This strategy includes three Phase 1b expansion cohorts, which have all been initiated during the first half of 2022 and build on the promising early clinical results during the company's Phase 1a trial.

ShowHide Related Items >><<
IMTX Immatics
$11.40 /

+0.17 (+1.51%)

IMTX Immatics
$11.40 /

+0.17 (+1.51%)

08/09/22 Chardan
Immatics price target lowered to $28 from $30 at Chardan
12/14/21 SVB Securities
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
12/14/21 SVB Securities
Immatics price target raised to $32 from $28 at SVB Leerink
IMTX Immatics
$11.40 /

+0.17 (+1.51%)

Recommendations
Immatics price target lowered to $28 from $30 at Chardan » 18:31
08/09/22
08/09
18:31
08/09/22
18:31
IMTX

Immatics

$12.47 /

-0.435 (-3.37%)

Chardan analyst Geulah…

Chardan analyst Geulah Livshits lowered the firm's price target on Immatics to $28 from $30 and keeps a Buy rating on the shares after the company reported Q2 results and "largely" reaffirmed guidance. The analyst said that the new price target is based on probability-adjusted modeling of key franchises. Livshits added that both MAGEA4/A8 modalities are "moving along," and that she expects "fairly limited" follow-up for ACTengine autologous TCR T-cell therapy cohorts.

ShowHide Related Items >><<
IMTX Immatics
$12.47 /

-0.435 (-3.37%)

IMTX Immatics
$12.47 /

-0.435 (-3.37%)

12/14/21 SVB Securities
SVB Leerink positive on Bristol-Myers deal, ups Immatics price target to $32
12/14/21 SVB Securities
Immatics price target raised to $32 from $28 at SVB Leerink
IMTX Immatics
$12.47 /

-0.435 (-3.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.